TOSYMRA achieves median peak plasma concentration faster than injectable Imitrex® (sumatriptan)1
- TOSYMRA is a novel nasal spray formulation of sumatriptan 10 mg developed with Intravail® technology1,2
- TOSYMRA with Intravail® technology, n-Dodecyl beta-D-maltoside or DDM, allows efficient transmucosal absorption of sumatriptan1
- Pharmacokinetic (PK) equivalence to a 4-mg subcutaneous (subQ) injection of Imitrex® (sumatriptan) has been shown1,2*
- Median peak plasma concentration of sumatriptan was observed 5 minutes faster with TOSYMRA compared with 4-mg and 6-mg subQ injections of Imitrex® (sumatriptan)1
*Following administration of a single dose of TOSYMRA in 73 healthy subjects, the relative bioavailability of sumatriptan was approximately 87% (90% confidence interval [CI]: 82-94) of that obtained following a 4-mg subQ injection of Imitrex® (sumatriptan).2
A 10-mg dose of TOSYMRA demonstrated a markedly increased rate and extent of sumatriptan absorption when compared with Imitrex® (sumatriptan) 20-mg nasal spray1
TOSYMRA achieved peak
median time of 15 minutes vs 120 minutes1
of TOSYMRA was
in the 2 hours following administration1
Mean peak plasma concentration
of TOSYMRA was
with half the dose
PK data indicates that minimal to no swallowing of sumatriptan occurred after administration of TOSYMRA1
- Double peaks† were observed for Imitrex® (sumatriptan) 20-mg nasal spray1
†Double peaks in plasma serum concentration suggest that only some of the sumatriptan was absorbed nasally after administration, while more of the drug was swallowed and absorbed through the gastrointestinal system at a later time.3
Each patient has a distinct migraine experience
Meet Jenn: has migraine-associated nausea
Jenn experiences migraines 2 to 4 times per month. Her migraines typically start as mild and then progress slowly to moderate-to-severe pain. Though gradual, these migraines can last up to 2 days, and relief is typically slow. Jenn also has a history of gastrointestinal (GI) distress and gastroparesis.
Jenn typically treats her migraines with oral triptans, but nausea makes it difficult for her to take her medication.
Typically, Jenn’s migraines are accompanied by nausea, requiring the addition of antiemetic medication. It is possible that gastroparesis has delayed the absorption of oral migraine treatment, leaving her with migraines that are often slow to respond to treatment.
- A migraine medication that provides rapid and effective relief
- An alternative to oral medication when she is nauseated
References: 1. Munjal S, Gautam A, Offman E, Brand-Schieber E, Allenby K, Fisher DM. A randomized trial comparing the pharmacokinetics, safety, and tolerability of DFN-02, an intranasal sumatriptan spray containing a permeation enhancer, with intranasal and subcutaneous sumatriptan in healthy adults. Headache. 2016;56(9):1455-1465. 2. TOSYMRA [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; 2019. 3. Wermeling DPH, Miller JD, Archer SM, Manaligod JM, Rudy AC. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol. 2001;41:1225-1231. 4. Data on file. Upsher-Smith Laboratories, Maple Grove, MN.